Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology · Merkel Cell Carcinoma

Decoding Your Pathology Report: Markers and Staging

At a Glance

Your Merkel cell carcinoma (MCC) pathology report uses markers like CK20 to confirm the diagnosis and TTF-1 to rule out lung cancer. Because MCC often spreads invisibly, checking your MCPyV virus status and performing a sentinel lymph node biopsy are critical for guiding your treatment.

Your pathology report is the roadmap for your treatment. It contains the results of tests performed on your biopsy sample to confirm the diagnosis and determine the “personality” of the tumor. Because Merkel cell carcinoma (MCC) is so rare, it is often necessary to distinguish it from other “small round blue cell” tumors, particularly metastatic small cell lung cancer (SCLC) [1][2].

The “Fingerprint”: Immunohistochemistry (IHC)

Pathologists use immunohistochemistry (IHC)—a process that uses special dyes to highlight specific proteins in your cells—to confirm that a tumor is MCC.

  • CK20 (Cytokeratin 20): This is the most important marker for MCC. In about 90% of cases, the pathologist will see a classic perinuclear dot-like pattern, where the dye forms tiny dots inside the cells [1][3].
  • TTF-1 (Thyroid Transcription Factor-1): This is a critical “rule-out” test. MCC is almost always negative for TTF-1, whereas small cell lung cancer is usually positive. If this marker is negative, it helps confirm the cancer started in the skin and not the lungs [3][1].
  • SATB2 and Synaptophysin: These are supplementary markers. SATB2 is highly specific for MCC and can help confirm the diagnosis in tricky cases where CK20 isn’t clear [4][5]. Synaptophysin confirms the tumor is a “neuroendocrine” type, which is the family of cancers MCC belongs to [6][7].

The Role of the Virus (MCPyV)

Your report may mention whether the tumor is MCPyV-positive (linked to the Merkel cell polyomavirus) or MCPyV-negative (usually caused by UV sun damage) [8][9].

  • MCPyV-Positive: These tumors are often considered highly “immunogenic,” meaning they may be more easily “seen” and attacked by your immune system [10][11]. Patients with virus-positive tumors generally have a slightly better overall survival outlook [12][13].
  • MCPyV-Negative: These tumors often have a higher number of genetic mutations caused by UV light. While historically considered more aggressive, they often respond very well to modern immunotherapy [8][14].

Why You Need a Sentinel Lymph Node Biopsy (SLNB)

Even if your lymph nodes feel normal during a physical exam (called “clinically node-negative”), MCC has a high rate of occult metastasis—microscopic cancer cells (hidden spread) that have traveled to the lymph nodes but are too small to be felt or seen on a standard scan [15][16].

Approximately 20% to 40% of patients with normal-feeling lymph nodes will actually have microscopic spread discovered during a Sentinel Lymph Node Biopsy (SLNB) [17][15]. Because of this high rate, an SLNB is considered the “gold standard” for accurate staging and is critical for deciding whether you need additional treatment like radiation or immunotherapy [18][19].

Pathology Report Checklist

Ensure your report or your doctor has addressed these key items:

  • [ ] Diagnosis confirmed as Merkel cell carcinoma.
  • [ ] CK20 status (usually positive) and TTF-1 status (usually negative).
  • [ ] Tumor size (measured in millimeters or centimeters).
  • [ ] Lymphovascular Invasion (LVI): Whether cancer cells were seen in the small blood or lymph vessels near the tumor [20][16].
  • [ ] Merkel cell polyomavirus (MCPyV) status (if tested).
  • [ ] Surgical margins: How close the cancer cells were to the edge of the removed tissue [21].

Common questions in this guide

What does a CK20 positive result mean for Merkel cell carcinoma?
A positive CK20 test, particularly showing a tiny dot-like pattern inside the cells, is the most important marker for Merkel cell carcinoma. It helps pathologists confirm the diagnosis and distinguish it from other types of cancer.
Why is a TTF-1 test performed if I have skin cancer?
TTF-1 is a marker used to rule out small cell lung cancer that has spread to the skin, which can look identical to MCC under a microscope. MCC is typically negative for TTF-1, while lung cancer is usually positive.
Does having a Merkel cell polyomavirus (MCPyV) positive tumor change my prognosis?
Yes, patients whose tumors test positive for the Merkel cell polyomavirus (MCPyV) generally have a slightly better overall survival outlook. These virus-positive tumors are often more easily recognized and attacked by your immune system.
Do I need a sentinel lymph node biopsy if my nodes feel normal?
Yes. Merkel cell carcinoma has a high rate of microscopic spread to the lymph nodes, even when they feel completely normal during a physical exam. A sentinel lymph node biopsy is the gold standard for finding this hidden spread and deciding if further treatment is needed.
What is lymphovascular invasion (LVI) on my pathology report?
Lymphovascular invasion (LVI) means that cancer cells were seen inside the tiny blood or lymph vessels near the main tumor. This is an important detail for your doctor because it helps them understand the risk of the cancer spreading to other parts of your body.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report show 'perinuclear dot-like' staining for CK20?
  2. 2.Was TTF-1 testing performed to rule out small cell lung cancer?
  3. 3.Given that my lymph nodes feel normal, when will we schedule my sentinel lymph node biopsy (SLNB)?
  4. 4.Was my tumor tested for the Merkel cell polyomavirus (MCPyV)? If so, what was the result?
  5. 5.What was the measured depth (Breslow thickness) and was there any lymphovascular invasion (LVI)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Neurofilament is superior to cytokeratin 20 in supporting cutaneous origin for neuroendocrine carcinoma.

    Stanoszek LM, Chan MP, Palanisamy N, et al.

    Histopathology 2019; (74(3)):504-513 doi:10.1111/his.13758.

    PMID: 30239030
  2. 2

    Merkel Cell Carcinoma Display PIEZO2 Immunoreactivity.

    García-Mesa Y, Martín-Sanz R, García-Piqueras J, et al.

    Journal of personalized medicine 2022; (12(6)) doi:10.3390/jpm12060894.

    PMID: 35743679
  3. 3

    Immunohistochemical profiles of different subsets of Merkel cell carcinoma.

    Pasternak S, Carter MD, Ly TY, et al.

    Human pathology 2018; (82()):232-238 doi:10.1016/j.humpath.2018.07.022.

    PMID: 30067951
  4. 4

    SATB2 is expressed in Merkel cell carcinoma.

    Fukuhara M, Agnarsdóttir M, Edqvist PH, et al.

    Archives of dermatological research 2016; (308(6)):449-54 doi:10.1007/s00403-016-1655-6.

    PMID: 27262585
  5. 5

    SATB2, CKAE1/AE3, and synaptophysin as a sensitive immunohistochemical panel for the detection of lymph node metastases of Merkel cell carcinoma.

    Szumera-Cieckiewicz A, Massi D, Cassisa A, et al.

    Virchows Archiv : an international journal of pathology 2024; (484(4)):629-636 doi:10.1007/s00428-023-03691-7.

    PMID: 38066198
  6. 6

    Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma).

    Rush PS, Rosenbaum JN, Roy M, et al.

    Journal of cutaneous pathology 2018; (45(2)):129-135 doi:10.1111/cup.13079.

    PMID: 29148079
  7. 7

    Merkel Cell Carcinoma: From Pathobiology to Clinical Management.

    Farooq Baba PU, Rasool Z, Younas Khan I, et al.

    Biology 2021; (10(12)) doi:10.3390/biology10121293.

    PMID: 34943208
  8. 8

    Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.

    Gauci ML, Aristei C, Becker JC, et al.

    European journal of cancer (Oxford, England : 1990) 2022; (171()):203-231 doi:10.1016/j.ejca.2022.03.043.

    PMID: 35732101
  9. 9

    Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma.

    Starrett GJ, Marcelus C, Cantalupo PG, et al.

    mBio 2017; (8(1)) doi:10.1128/mBio.02079-16.

    PMID: 28049147
  10. 10

    Merkel Cell Carcinoma: New Trends.

    Zwijnenburg EM, Lubeek SFK, Werner JEM, et al.

    Cancers 2021; (13(7)) doi:10.3390/cancers13071614.

    PMID: 33807446
  11. 11

    The Role of the Large T Antigen in the Molecular Pathogenesis of Merkel Cell Carcinoma.

    Myrda J, Bremm F, Schaft N, Dörrie J

    Genes 2024; (15(9)) doi:10.3390/genes15091127.

    PMID: 39336718
  12. 12

    The impact of merkel cell polyomavirus positivity on prognosis of merkel cell carcinoma: A systematic review and meta-analysis.

    Yang A, Wijaya WA, Yang L, et al.

    Frontiers in oncology 2022; (12()):1020805 doi:10.3389/fonc.2022.1020805.

    PMID: 36248985
  13. 13

    Merkel Cell Carcinoma Case Reports With Merkel Cell Polyomavirus Test and Review of the Literature.

    Chai J, Tang Y, Chen Y, Liu Y

    The American Journal of dermatopathology 2024; (46(11)):784-787 doi:10.1097/DAD.0000000000002837.

    PMID: 39288754
  14. 14

    Structure of Merkel Cell Polyomavirus Capsid and Interaction with Its Glycosaminoglycan Attachment Receptor.

    Bayer NJ, Januliene D, Zocher G, et al.

    Journal of virology 2020; (94(20)) doi:10.1128/JVI.01664-19.

    PMID: 32699083
  15. 15

    Sentinel lymph node biopsy in clinically node-negative Merkel cell carcinoma: the Westmead Hospital experience.

    Jenkins LN, Howle JR, Veness MJ

    ANZ journal of surgery 2019; (89(5)):520-523 doi:10.1111/ans.15228.

    PMID: 30959572
  16. 16

    Effect of Sentinel Lymph Node Biopsy and LVI on Merkel Cell Carcinoma Prognosis and Treatment.

    Harounian JA, Molin N, Galloway TJ, et al.

    The Laryngoscope 2021; (131(3)):E828-E835 doi:10.1002/lary.28866.

    PMID: 32663337
  17. 17

    Systematic review of sentinel lymph node biopsy in Merkel cell carcinoma of the head and neck.

    Karunaratne YG, Gunaratne DA, Veness MJ

    Head & neck 2018; (40(12)):2704-2713 doi:10.1002/hed.25345.

    PMID: 29934958
  18. 18

    Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy.

    Dugan MM, Balsay-Patel C, Chin N, et al.

    Annals of surgical oncology 2026; (33(1)):389-396 doi:10.1245/s10434-025-18618-6.

    PMID: 41168606
  19. 19

    Outcomes of Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma.

    Bartlett EK, Kalvin HL, Barker CA, et al.

    Annals of surgical oncology 2025; doi:10.1245/s10434-025-18792-7.

    PMID: 41291356
  20. 20

    Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma.

    Smith FO, Yue B, Marzban SS, et al.

    Cancer 2015; (121(18)):3252-60 doi:10.1002/cncr.29452.

    PMID: 26038193
  21. 21

    Updates on Merkel Cell Carcinoma.

    Emge DA, Cardones AR

    Dermatologic clinics 2019; (37(4)):489-503 doi:10.1016/j.det.2019.06.002.

    PMID: 31466589

This page explains Merkel cell carcinoma pathology terminology for educational purposes only. Always consult your pathologist and oncologist for the interpretation of your specific biopsy results.

Get notified when new evidence is published on Cutaneous neuroendocrine carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.